Current Progress in Patient-Specific Drug Formulations

Review Article

Abstract

The pharmaceutical industry has witnessed a paradigm shift from traditional "one-size-fits-all" drug formulations toward personalized therapeutic approaches. This transformation has been driven by advancements in pharmaceutical technology, enabling the development of patient-specific formulations that consider individual genetic makeup, metabolic variations, and disease characteristics. Modern technologies, including 3D printing, microfluidics, and artificial intelligence, have emerged as powerful tools in manufacturing individualized drug formulations with precise dosing, targeted delivery, and optimized therapeutic outcomes. The application of 3D printing has enabled the production of complex dosage forms with tailored drug release profiles, while microfluidic platforms have facilitated the development of sophisticated drug delivery systems. Artificial intelligence and machine learning algorithms have enhanced formulation design by analyzing patient-specific data and predicting optimal drug-excipient combinations. These technological innovations have shown particular promise in oncology, rare diseases, and chronic conditions, where personalized approaches significantly impact treatment efficacy. However, the implementation of patient-specific formulations presents challenges in regulatory compliance, manufacturing scalability, and cost-effectiveness. The field requires standardized quality control protocols, specialized training programs, and robust data management systems. Additionally, regulatory frameworks must evolve to accommodate these innovative therapeutic approaches while ensuring patient safety and product quality.